PF-Atlas › Clinical Trials › NCT03864328
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
RVT-1601 · Phase 2
Registry ID
NCT03864328
Phase
Phase 2
Status
Terminated
Drug / intervention
RVT-1601
Sponsor
Respivant Sciences GmbH
Start
2019-03-29
Enrollment
108
Locations
81
About this trial
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by exertional dyspnea and persistent dry cough. Cough in IPF is both a presenting and a complicating clinical feature, which affects approximately three quarters of IPF cases. It is often a debilitating symptom that adversely affects quality of life (QoL) and is usually refractory to medical therapy. Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, is being evaluated in this Phase 2b study for the treatment of persistent cough in patients with IPF.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03864328 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.